Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cell Injection Combined With Standard Maintenance Therapy in Advanced Solid Tumors
NCT07551778Phase 2Not yet recruiting
- Sponsor
- BOE Technology Group
- Start
- Aug 2026
- Primary completion
- Apr 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 2, open-label trial of AlloNK in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), hepatocellular carcinoma (HCC) and 2 more (5 cohorts), sponsored by BOE Technology Group. Primary endpoints: Dose-Limiting Toxicity at 14 days and Adverse Events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
AlloNK
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)gastric cancer (GC)solid tumor
Beyond the preview
Go deeper on NCT07551778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551778.